BIIB021 (originally called CNF2024) is an oral inhibitor of heat shock protein 90 (HSP90) originally under development by Conforma Therapeutics. Following acquisition of Conforma, development is proceeding under the new owner, Biogen Idec, under the new name BIIB021. For information at the website of the manufacturer, link here.
In 2008 a new Phase II trial opened studying this drug against GIST: FDG-PET Pharmacodynamic Assessment of BIIB021 in GIST, ID NCT00618319. The preceding link lists the first two study sites as Memorial Sloan-Kettering Cancer Center and the Mayo Clinic in Minnesota.
The ongoing Phase I trial Study of Oral CNF2024 in Advanced Solid Tumors or Lymphomas is described at the site clinicaltrials.gov Study ID Numbers: CNF2024-ST-05003; 120ST101; NCT000345189. Trial sites include Scottsdale, AZ, New Haven, CT, San Antonio, TX, and the United Kingdom. This is a Phase I dose escalation study. The drug is administered orally twice weekly for three weeks of a four-week course.
Another separate Phase I trial to test daily dosing of BIIB021 is listed at clinicaltrials.gov as study ID NCT00618735, but it is not yet recruiting as of March 2008.
Here is a link to a very detailed scientific article in Medscape about
Here is a link to information about Hsp90 in Wikipedia.